

Review

Application of da Vinci robots in the surgery of selected human cancers

Yusuf Jamal¹, Fahad M. Al-Khodairy^{2*}

¹Ternopil National Medical University, Ternopil, Ukraine

²King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia



ARTICLE INFO

Article history

Received 16 November 2021,
Revised 21 November 2021,
Accepted 12 December 2021,
Published online
30 December 2021

Keywords

Da Vinci, Robotic Surgery,
Cancers, Oncological Outcomes

ABSTRACT

The discovery of da Vinci surgical systems significantly contributed to cancer surgeries worldwide, however, the clinical and oncological outcomes are still debatable. Many retrospective studies have highlighted the advantage of robotic surgery over laparoscopic or open surgical procedures for various cancers, however, more multicentered, coordinated, random clinical trials must be conducted to outline the specific advantages of da Vinci robots. They have been widely used in cancer surgeries, however, higher operative cost and comparable oncological outcomes with laparoscopic approaches further forced manufacturers to come up with affordable and efficient specialized robotic surgery systems. Nevertheless, robotic surgery using da Vinci robots has been widely accepted for hysterectomy and prostatectomy over the laparoscopic procedure and this review briefly discusses da Vinci robots in the surgery of various human cancers and their clinical outcomes.

Background

For the past few decades, minimally invasive surgery (MIS) has been a popular surgical approach for certain cancers due to reduced incision size, less wound trauma, discomfort, recovery time, and cost. Further, many researchers started to use robots to assist surgeons in performing surgeries for better surgical precision. Robotic Surgery (RS) was introduced almost three decades ago and has since been applied for surgery of various cancers.

One of the widely used RS in modern times was the da Vinci surgical system which was developed by Intuitive Surgical (USA) in 2000. Later it was approved by the Food and Drug Administration (FDA) for prostatectomies, cardiac valve repair, and gynecological surgeries.^{1,2} Despite being costly along with the software issues, over 5,582 da Vinci surgical systems have been installed worldwide and an estimated >1.2 million surgeries have been performed worldwide till the end of 2020.³ In the USA, da Vinci robotic surgeries are the leading option for women with gynecologic cancers while some 86% with prostate cancer opted for prostatectomy.¹ This system has been applied in many surgical procedures such as hysterectomy, sacrocolpopexy, prostatectomy, partial nephrectomy, cardiothoracic thoracic surgery, mitral valve repair, hernia repair, colorectal, cholecystectomy, bariatric and transoral surgeries.³ With

*Corresponding author at: King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

E-mail address: khodairy@kfshrc.edu.sa

<https://orcid.org/0000-0002-7860-5574>

<https://doi.org/10.37881/1.634>

better perioperative, oncological, and functional outcomes in robotic surgical procedures seem to be the next evolutionary step in patient safety, high efficacy, and precision surgery.³⁻¹¹


Methods

Using keywords like da Vinci robots, laparoscopic surgery, robotic surgery in lung, liver, colorectal, gastric, breast, prostate, and gynecological cancer in PubMed and Google Scholar, relevant original articles and reviews, case reports, randomized and non-randomized controlled trials, cohort studies from 2010-2021 were systematically reviewed.

Results

Our search resulted in 300 publications and browsing the titles further reduced the numbers to 200 (Figure 1). After assessing the abstracts for duplicate, and irrelevant data to our review scope, an additional 95 were excluded. Out of 70 full-length articles, 15 articles were excluded due to overlapping, irrelevant data and inconclusive data and finally 55 relevant studies (breast cancer, prostate cancer, and gynecological cancers) were included in this review.

Figure 1: PRISMA flow diagram for selection of relevant studies.



Breast Cancer

Endoscopic breast operation in an aesthetic sense was an option to achieve full cancer clearance while simultaneously preserving the patient's physique.¹² Due to inflexible endoscopic equipment and 2-dimensional cameras in this technique has severely limited the maneuverability and insufficient area of the operating field.¹³ The da Vinci robotic surgical systems provided a clearer three-dimensional surgical view, minimal incision, stable and flexible mechanical arms, high precision, and lower complication rates and traumatization.^{10,14} Several studies have reported that the nipple-sparing mastectomy may be the valid endoscopic procedure therapeutic mastectomy of breast cancer.¹⁵⁻²¹ For early breast cancer and benign conditions, a combination of robot-assisted Nipple-sparing Mastectomy (RANSM) along with immediate breast reconstruction (IBR) is a surgically safe and feasible approach.^{13,15-21} It has been observed that RANSM combined with IBR resulted in a comparatively better outcome, quick post-operative recovery, and patient satisfaction than the Conventional Nipple-sparing Mastectomy (CNSM) followed by IBR.^{14,22} However, RANSM with IBR has an associated drawback of longer operation time and higher cost. The da Vinci robotic systems could also be used in male mastectomy and internal mammary lymph node biopsy.^{23,24} A recent comparative study revealed that da Vinci robot-assisted axillary lymph node dissection (dVALND) improved the overall quality of life in breast cancer patients by mitigating postoperative complications with minimal local recurrence, metastasis, or aesthetic effect than axillary lymph node dissection (ALND).²⁵

Prostate Cancer

Prostatectomy is an extremely delicate surgery requiring high surgical precision because of the presence of blood vessels, muscles, and nerve bundles in very close proximity to each other as well as innervating the erectile and bladder functions. In case of metastasis, prostatectomy is generally not recommended due to its delicate structure. There have been several surgical approaches to implement Robot-Assisted Radical Prostatectomy (RARP) however it is still questionable whether it is oncologically safe.²⁶ Possible negative outcomes of RARP include erectile dysfunction and Postoperative Prostatectomy Incontinence (PPI).²⁷ The most used approach is Retzius-sparing RARP which has been effective in quicker recovery from urinary incontinence.^{26,28} Despite this side effect, RARP was opted by 86% of prostate cancer patients in the United States.¹

In a few meta-analysis studies, RARP resulted in better overall short-term outcomes regarding reduced hospital stay and blood loss and oncologically safe compared to LRP or open radical prostatectomy (ORP).²⁹⁻³¹ In addition, nerve-sparing, and early recovery from urinary incontinence and erectile dysfunction were also observed.²⁹⁻³¹ In a previous report, similar short-term outcomes were observed with no difference in urinary and sexual quality of life in RARP, LRP, or ORP. However, more and more evidence and randomized controlled trials are required to verify the safety of the RARP approach.³² Generally, percutaneous drainage, sclerosing agents, and surgical marsupialization, are being used as treatment modalities for symptomatic lymphoceles which are typically performed by laparoscopy or with a multiport robotic platform. However, Moschovas et al (2021) used da Vinci single port lymphoectomy in the treatment of the lymphocele sac, which reduced the number of days with abdominal drains, and decreased surgical invasiveness with fewer incisions, less operative time, and blood loss, and better cosmesis.³³ Further, no intraoperative or postoperative complications were reported.³³

Earlier, Steinberg et al (2019) in a multi-institutional initial case series using magnet-assisted robotic prostatectomy and the Single Port da Vinci robotic platform achieved average operative time, less blood loss, early discharge with no intraoperative or postoperative complications.³⁴ This report suggested that

the combination of Robotic prostatectomy (RP) utilizing the da Vinci Single Port system with the magnetic retractor (Levita™ Magnetic Surgical System, San Mateo, CA, USA), can be effective, feasible, and safe. The magnetic retractor facilitated tissue exposure with improved procedure ergonomics by mimicking the conventional multiport technique. However, the use of magnets in robotic surgery and optimization of assistant port placement for true single-site surgery need to be further explored.³⁴

Gynecological Cancers

Gynecologic cancers which include cancers of the ovary, uterine, cervical, vulvar, and vaginal are some of the very prominent cancers for females after breast cancer. Based on the stage of cancer, the localization of the tumor, and involvement of other organs in the pelvic cavity, hysterectomy is a widely implemented surgical procedure. Even though the first total laparoscopic radical hysterectomy (TLRH) was performed in 1989, however, till 1992, surgical treatment for gynecological cancers using open surgery (OS) has been the standard procedure.^{35,36} Laparoscopic radical hysterectomy (LRH) proved to be beneficial over the traditional open abdominal approach such as relatively less blood loss, preservation of soft tissues, faster wound healing, and less recovery time.^{37,38} However, patient survival and success rate were the same in both OS and LRH with a difference in a higher cost for LRH.³⁹ Furthermore, there are inherent ergonomic drawbacks like the posture of the surgeon performing the surgery, the 2D visuals of the surgical site, and the maneuverability of the laparoscopic instruments in LRH.^{40,41}

With the approval of the da Vinci surgical system by the USFDA in 2005, the Robot-Assisted Radical Hysterectomy (RARH) for gynecological surgeries was opted by many surgeons due to its superior maneuverability, 3D visualization of the target site, relatively easy learning curve, and better ergonomics compared to the laparoscopic methods.^{2,42-45} Few randomized controlled trials have reported that the RARH provides superiority over LRH in terms of blood loss, operative time, maneuverability, hospital stay, and postoperative complications.⁴⁶⁻⁴⁸ In recent times, both LRH and RARH have been widely used in the treatment of gynecological cancers for safety, feasibility with comparatively fewer postoperative complications, and better quality of life.⁴⁹⁻⁵⁵

Conclusion and Future Perspectives

Since the inception of robotic surgery in 1985, it has been widely used in various fields, due to its high-resolution, several-fold image magnifications with 3D optics enabled intercostal perforators and lymphatics to be accurately visualized and differentiated. The complex and intuitive motion of the robotic arms in da Vinci robots allows surgeons to accurately perform delicate surgeries. On one hand, da Vinci robotic surgical systems provide high precision, shorter hospital stays, less intraoperative blood loss over laparoscopic surgery, however, its higher operational cost and longer operative time with similar oncological outcomes as laparoscopic surgery have been cited in several retrospective studies. Lack of quality randomized multicentered controlled international trials to compare the robotic versus laparoscopic versus open approaches is urgently needed. Nevertheless, da Vinci robotic surgical systems have widely opted in hysterectomy and prostatectomy and to cut down the installation and operative cost, a collaborative Robotics Surgery Hospital can be set up by pooling the resources and manpower from various government and private hospitals. Further, in addition to da Vinci Surgical Systems, several specific robots are being developed such as PRECEYES Surgical System (Preceyes B.V, The Netherlands) and Versius Surgical Systems (CMR Surgical Ltd, UK) for specific surgeries to be cost-effective.

Acknowledgment

Yusuf Jamal is pursuing an MBBS degree from TNMU, Ukraine.

Conflicts of Interest

The authors declare that there are no conflicts of interest relevant to this article.

List of Abbreviations

ALND- Axillary Lymph Node Dissection
CNM- Conventional Nipple-sparing Mastectomy
dVALND- da Vinci Robot-Assisted Axillary Lymph Node Dissection
FDA- Food and Drug Administration
IBR- Immediate Breast Reconstruction
MIS- Minimally Invasive Surgery
ORP- Open Radical Prostatectomy
OS- Open Surgery
PPI- Postoperative Prostatectomy Incontinence
RP- Radical Prostatectomy
RS- Robotic Surgery
RARP- Robot-Assisted Radical Prostatectomy
LRH- Laparoscopic Radical Hysterectomy
RANSM- Robot-assisted Nipple-sparing Mastectomy
RARH- Robot-Assisted Radical Hysterectomy
TLRH- Total Laparoscopic Radical Hysterectomy

References

1. Crew, B. A closer look at a revered robot. *Nature* 2020;580: S5-S7
2. Netter, A., Jauffret, C., Brun, C., Sabiani, L., Blache, G., Houvenaeghel, G., & Lambaudie, E. Choosing the most appropriate minimally invasive approach to treat gynecologic cancers in the context of an enhanced recovery program: Insights from a comprehensive cancer center. *Plos One* 2020; 15(4):e0231793.
3. Intuitive Surgical Inc. (USA) Annual Report 2018, https://www.annualreports.com/HostedData/AnnualReportArchive/i/NASDAQ_ISR_2018.pdf (accessed on Dec 08, 2021).
4. Perets I, Walsh JP, Close MR, Mu BH, Yuen LC, Domb BG. Robot-assisted total hip arthroplasty: clinical outcomes and complication rate. *Int J Med Robot Comput Assist Surg.* 2018; 14(4):e1912.
5. Magistri P, Tarantino G, Assirati G, et al. Robotic liver resection for hepatocellular carcinoma: a systematic review. *Int J Med Robot Comput Assist Surg.* 2019; 15(4):e2004.
6. Jun Y, Hao L, Demin L, Guohua D, Hua J, Yi S. Da Vinci robot-assisted system for thymectomy: experience of 55 patients in China. *Int J Med Robot Comput Assist Surg.* 2014; 10(3): 294- 299.
7. Morelli L, Guadagni S, Di Franco G, et al. Use of the new da Vinci Xi® during robotic rectal resection for cancer: a pilot matched-case comparison with the da Vinci Si®. *Int J Med Robot Comput Assist Surg.* 2017; 13(1):e1728.
8. Morel P, Jung M, Cornateanu S, et al. Robotic versus open liver resections: a case-matched comparison. *Int J Med Robot Comput Assist Surg.* 2017; 13(3):e1800.
9. Taylor G, Jayne D. Robotic applications in abdominal surgery: their limitations and future developments. *Int J Med Robot Comput Assist Surg.* 2007; 3(1): 3- 9.
10. Feldstein J, Schwander B, Roberts M, Coussons H. Cost of ownership assessment for a da Vinci robot based on US real-world data. *Int J Med Robot Comput Assist Surg.* 2019; 15(5):e2023.
11. Stadler P, Dvoracek L, Vitasek P, Matous P. Robotic vascular surgery, 150 cases. *Int J Med Robot Comput Assist Surg.* 2010; 6(4): 394- 398.
12. Leff DR, et al. Endoscopic breast surgery: where are we now and what might the future hold for video-

- assisted breast surgery? *Breast cancer research and treatment*. 2011; 125:607–625.
13. Toesca A, Peradze N, Manconi A, Galimberti V, Intra M, Colleoni M et al. Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. *Breast (Edinburgh, Scotland)* 2017;31:51–56.
 14. Park BJ, Melfi F, Mussi A, Maisonneuve P, Spaggiari L, Da Silva RK, et al. Robotic lobectomy for non-small cell lung cancer (NSCLC): long-term oncologic results. *J Thorac Cardiovasc Surg*. 2012; 143:383–389.
 15. Smith BL, Tang R, Rai U, et al. Oncologic safety of nipple-sparing mastectomy in women with breast cancer. *J Am Coll Surg*. 2017; 225(3): 361- 365.
 16. Li M, Chen K, Liu F, Su F, Li S, Zhu L. Nipple sparing mastectomy in breast cancer patients and long-term survival outcomes: an analysis of the SEER database. *PloS One*. 2017; 12(8):e0183448.
 17. Muller T, Baratte A, Bruant-Rodier C, Bodin F, Mathelin C. Oncological safety of nipple-sparing prophylactic mastectomy: a review of the literature on 3716 cases. *Ann Chir Plast Esthet*. 2018; 63: e6- e13.
 18. Galimberti V, Vicini E, Corso G, et al. Nipple-sparing and skin-sparing mastectomy: review of aims, oncological safety and contraindications. *Breast*. 2017; 34: S82- S84.
 19. De Vita R, Zoccali G, Buccheri EM, Costantini M, Botti C, Pozzi M. Outcome evaluation after 2023 nipple-sparing mastectomies: our experience. *Plast Reconstr Surg*. 2017; 139(2): 335e- 347e.
 20. Houvenaeghel G, Bannier M, Rua S, et al. Breast cancer robotic nipple sparing mastectomy: evaluation of several surgical procedures and learning curve. *World J Surg Oncol*. 2019; 17(1): 1- 11.
 21. Chen K, Beeraka NM, Li J, Lu P. Anterior abdominal wall defect closed by the anterior sheath of the upper rectus abdominis muscle in a patient with prior “TRAM flap breast reconstruction”. *Indian J Surg*. 2021: 1-3.
 22. Lai HW, Chen ST, Mok CW, Lin YJ, Wu HK, Lin SL et al. Robotic versus conventional nipple sparing mastectomy and immediate gel implant breast reconstruction in the management of breast cancer- A case control comparison study with analysis of clinical outcome, medical cost, and patient-reported cosmetic results. *J Plast Reconstr Aesthet Surg*. 2020; 73:1514-1525.
 23. Melly L, Jansens J-L, Kalscheuer G, Belhaj A, Rondelet B. Robotic lymphadenectomy of an internal mammary lymph node metastasis. *Acta Chir Belg*. 2018; 118(5): 320- 321.
 24. Kuo C, Sukortseva N, Sinelnikov M, Nassilevsky P, Reshetov I. A case of breast surgery with da vinci robotics. *Revista Latinoamericana de Hipertension*. 2019; 14(1): 70- 73.
 25. Chen K, M Beeraka N, Zhang J, Reshetov IV, Nikolenko VN, Sinelnikov MY, Mikhaleva LM. Efficacy of da Vinci robot-assisted lymph node surgery than conventional axillary lymph node dissection in breast cancer - A comparative study. *Int J Med Robot*. 2021 Dec;17(6):e2307. doi: 10.1002/rcs.2307. Epub 2021 Jul 29. PMID: 34270843.
 26. Martini A, Falagario UG, Villers A, Dell'Oglio P, Mazzone E, Autorino R et al. Contemporary techniques of prostate dissection for robot-assisted prostatectomy. *Eur Urol*. 2020;78(4):583-591.
 27. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. *Eur Urol* 2017;71(4):618-629.
 28. Collette E, Klaver S, Lissenberg-Witte B, van den Ouden D, van Moorselaar R, Vis A. Patient reported outcome measures concerning urinary incontinence after robot assisted radical prostatectomy: development and validation of an online prediction model using clinical parameters, lower urinary tract symptoms and surgical experience. *J Robotic Surg* 2021; 15, 593–602.
 29. Du Y, Long Q, Guan B, Mu L, Tian J, Jiang Y et al. Robot-assisted radical prostatectomy is more beneficial for prostate cancer patients: a system review and meta-analysis. *Med Sci Monit* 2018; 24:272-287.
 30. Theisen KM, Myrnga JM, Hale N, et al. Excessive opioid prescribing after major urologic procedures. *Urol* 2019; 123:101–107.
 31. Mazzone E, Dell'Oglio P, Rosiello G, Puliatti S, Brook N, Turri F et al. Technical refinements in super extended robot-assisted radical prostatectomy for locally advanced prostate cancer patients at multiparametric magnetic resonance imaging. *Eur Urol* 2021; 80(1):104-112.
 32. Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M. Laparoscopic and robotic-assisted versus open

- radical prostatectomy for the treatment of localized prostate cancer. *Cochrane Database Syst Rev.* 2017;9(9):CD009625.
33. Covas Moschovas M, Helman T, Reddy S, Bhat S, Rogers T, Sandri M, Noel J, Patel V. Minimally invasive lymphocele drainage using the da Vinci single-port platform: step-by-step technique of a prostate cancer referral center. *J Endourol.* 2021 Sep;35(9):1357-1364.
 34. Steinberg RL, Johnson BA, Meskawi M, Gettman MT and Cadeddu JA. Magnet-assisted robotic prostatectomy using the da Vinci SP robot: an initial case series. *J Endourol.* 2019 Oct; 33(10): 829-834.
 35. Canis M, Maze G, Wattiez A, Pouly J, Chapron C, Bruhat M. Vaginally assisted laparoscopic radical hysterectomy. *J Gynecol Surg.* 1992;8:103-105.
 36. Nezhat CR, Burrell MO, Nezhat FR, Benigno BB, Welander CE. Laparoscopic radical hysterectomy with paraaortic and pelvic node dissection. *Am J Obstet Gynecol.* 1992;166(3):864-865.
 37. Sharma R, Bailey J, Anderson R, Murdoch J. Laparoscopically assisted radical vaginal hysterectomy (Coelio-Schauta): a comparison with open Wertheim/Meigs hysterectomy. *Int J Gynecol Cancer.* 2006; 16:1927-1932.
 38. Renato S, Mohamed M, Serena S, Giulia M, Giulia F, Giulia G et al. Robot-assisted radical hysterectomy for cervical cancer: review of surgical and oncological outcomes. *ISRN Obstet Gynecol.* 2011; 2011:872434.
 39. Zakashansky K, Chuang L, Gretz H, Nagarsheth NP, Rahaman J, Nezhat FR. A case-controlled study of total laparoscopic radical hysterectomy with pelvic lymphadenectomy versus radical abdominal hysterectomy in a fellowship training program. *Int J Gynecol Cancer.* 2007;17(5):1075-1082.
 40. Berguer R. Surgery and ergonomics. *Arch Surg.* 1999;134(9):1011-1016.
 41. Dakin GF, Gagner M. Comparison of laparoscopic skills performance between standard instruments and two surgical robotic systems. *Surg Endosc.* 2003;17(4):574-579.
 42. Advincula AP, Wang K. Evolving role and current state of robotics in minimally invasive gynecologic surgery. *J Minim Invasive Gynecol* 2009; 16:291-301.
 43. Holloway RW, Patel SD, Ahmad S. Robotic Surgery in Gynecology. *Scan J Surg;* 2009;98(2):96-109.
 44. Nezhat FR, Datta MS, Liu C, Chuang L, Zakashansky K. Robotic radical hysterectomy versus total laparoscopic radical hysterectomy with pelvic lymphadenectomy for treatment of early cervical cancer. *JLS.* 2008;12(3):227-237.
 45. Hassan SO, Dudhia J, Syed LH, Patel K, Farshidpour M, Cunningham SC, et al. Conventional Laparoscopic vs Robotic Training: Which is Better for Naive Users? A Randomized Prospective Crossover Study. *J Surg Educ.* 2015;72: 592-599.
 46. Netter A, Jauffret C, Brun C, Sabiani L, Blache G, Houvenaeghel G et al. Choosing the most appropriate minimally invasive approach to treat gynecologic cancers in the context of an enhanced recovery program: Insights from a comprehensive cancer center. *PLoS One.* 2020;15(4):e0231793.
 47. Luo C, Liu M, Li X. Efficacy, and safety outcomes of robotic radical hysterectomy in Chinese older women with cervical cancer compared with laparoscopic radical hysterectomy. *BMC Women's Health.* 2018;18(1).
 48. Maenpaa MM, Nieminen K, Tomas EI, Laurila M, Luukkaala TH, Maenpaa JU. Robotic-assisted vs traditional laparoscopic surgery for endometrial cancer: a randomized controlled trial. *Am J Obstet Gynecol.* 2016;215(5): 588.e1-588.e7.
 49. Salehi S, Brandberg Y, Åvall-Lundqvist E, Suzuki C, Johansson H, Legerstam B et al. Long-term quality of life after comprehensive surgical staging of high-risk endometrial cancer - results from the RASHEC trial. *Acta Oncol.* 2018;57(12):1671-1676.
 50. Giannini A, Russo E, Mannella P, Palla G, Pisaneschi S, Cecchi et al. First series of total robotic hysterectomy (TRH) using new integrated table motion for the da Vinci Xi: feasibility, safety, and efficacy. *Surgical Endoscopy.* 2017 Aug;31(8):3405-3410.
 51. Abel MK, Chan JK, Chow S, Darcy K, Tian C, Kapp DS et al. Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer. *Int J Gynecol Cancer* 2020; 30:1347-1355.

52. Chang WF, Luo AJ, Yuan YF, Chen Y, Xin ZR, Xu SS. Perioperative Complications and Safety Evaluation of Robot-Assisted Radical Hysterectomy of Cervical Cancer After Neoadjuvant Chemotherapy. *Cancer Manag Res.* 2020; 12:4483-4492.
53. El-Achi V, Weishaupt J, Carter J, Saidi S. Robotic versus laparoscopic hysterectomy in morbidly obese women for endometrial cancer. *J Robotic Surg* 2021; 15:483–487.
54. Mereu L, Berlanda V, Surico D, Gardella B, Pertile R, Spinillo A et al. Evaluation of quality of life, body image and surgical outcomes of robotic total laparoscopic hysterectomy and sentinel lymph node mapping in low-risk endometrial cancer patients - A Robotic Gyne Club study. *Acta Obstetrica et Gynecologica Scandinavica.* 2020 Sep;99(9):1238-1245.
55. Nasioudis D, Frey M.K, Chapman-Davis E, Caputo T.A & Holcomb K. Outcomes of minimally invasive surgery for patients with endometrial carcinoma involving the cervix. *Int J Gynecol Cancer* 2020; 30:619-625.

Cite this article

Jamal Y, Al-Khodairy F. Application of da Vinci robots in the surgery of selected human cancers. *NeuroPharmac J.* 2021; 6(3): 253-260. DOI: 10.37881/1.634

Copyright

© 2021 NeuroPharmac J. This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License.